EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie

View source ↗

Summary

The EMA authorised Dupixent (dupilumab) for multiple EU indications, including atopic dermatitis, prurigo nodularis, eosinophilic esophagitis, asthma, and chron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Atopic Dermatitis
• Eosinophilic Esophagitis
• Prurigo Nodularis
• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Status: Authorised. Therapeutic area: Dermatitis, Atopic;Prurigo;Esophageal Diseases;Asthma;Sinusitis. MAH: Sanofi Winthrop Industrie. Decision date: 10/04/2026